atezolizumab

Home
Ligands
atezolizumab

GtoPdb Ligand ID: 7990

Synonyms: MPDL3280A | Tecentriq®

atezolizumab is an approved drug (FDA (2016), EMA (2017))

Comment: Atezolizumab (MPDL3280A) is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence analysis using the light chain variable region of atezolizumab provides a 100% match to sequence 21 from patent US8217149. An X-ray crystal structure of the PD-L1/atezolizumab complex has been submitted to the RCSB PDB (accession 5X8L) [6].

References
1. Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda LA, Shearer-Kang E, Liu X, Tosti N, Williams P, Castro Sanchez AY et al.. (2024) Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC. J Thorac Oncol, 19 (10): 1460-1466. [PMID:38729426]
2. Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, Chan P, Shearer-Kang E, Liu X, Tosti N et al.. (2023) IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol, 34 (8): 693-702. [PMID:37268157]
3. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M et al.. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med, 379 (23): 2220-2229. [PMID:30280641]
4. Inoue Y. (2024) Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?. Transl Lung Cancer Res, 13 (4): 947-951. [PMID:38736492]
5. Irving B, Chiu H, Maecker H, Mariathasan S, Lehar SM, Wu Y, Cheung J. (2012) Anti-PD-L1 antibodies, compositions and articles of manufacture. Patent number: US8217149. Assignee: Genentech, Inc.. Priority date: 09/12/2008. Publication date: 10/07/2012.
6. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep, 7 (1): 5532. [PMID:28717238]
7. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12 (4): 252-64. [PMID:22437870]
8. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC et al.. (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389 (10066): 255-265. [PMID:27979383]
9. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F et al.. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 378 (24): 2288-2301. [PMID:29863955]
10. Topalian SL, Drake CG, Pardoll DM. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 27 (4): 450-61. [PMID:25858804]

References

1. Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda LA, Shearer-Kang E, Liu X, Tosti N, Williams P, Castro Sanchez AY et al.. (2024)
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
J Thorac Oncol, 19 (10): 1460-1466. [PMID:38729426]

2. Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, Chan P, Shearer-Kang E, Liu X, Tosti N et al.. (2023)
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Ann Oncol, 34 (8): 693-702. [PMID:37268157]

3. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M et al.. (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med, 379 (23): 2220-2229. [PMID:30280641]

4. Inoue Y. (2024)
Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?.
Transl Lung Cancer Res, 13 (4): 947-951. [PMID:38736492]

5. Irving B, Chiu H, Maecker H, Mariathasan S, Lehar SM, Wu Y, Cheung J. (2012)
Anti-PD-L1 antibodies, compositions and articles of manufacture.
Patent number: US8217149. Assignee: Genentech, Inc.. Priority date: 09/12/2008. Publication date: 10/07/2012.

6. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Sci Rep, 7 (1): 5532. [PMID:28717238]

7. Pardoll DM. (2012)
The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer, 12 (4): 252-64. [PMID:22437870]

8. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC et al.. (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet, 389 (10066): 255-265. [PMID:27979383]

9. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F et al.. (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med, 378 (24): 2288-2301. [PMID:29863955]

10. Topalian SL, Drake CG, Pardoll DM. (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell, 27 (4): 450-61. [PMID:25858804]